Daiichi Sankyo Shares Plunge After Delaying Q4 Results

Daiichi Sankyo Stock Tumbles Over 10%

Japanese pharmaceutical company Daiichi Sankyo experienced a significant 10.4% drop in its share price on Thursday. The decline was a direct response to the company's announcement of a second postponement for its fourth-quarter financial results and its new medium-term strategic plan.

Overview of the Situation

The company has rescheduled the joint release of its results and plan to May 11. Daiichi Sankyo stated it requires additional time to accurately estimate a loss compensation provision. This provision is linked to a contract development and manufacturing organization for a product currently in the development phase.

Market Impact and Analysis

This development follows a previously recorded provision of ¥12.7 billion related to its HER3 drug candidate. Analysts from Morgan Stanley believe this new charge is an additional HER3-related provision, suggesting a potential delay in the product's launch timeline. The market impact may be limited, as expectations for HER3 are reportedly subdued.

Summary

The repeated delays and the need for new financial provisions have introduced uncertainty among investors, prompting a notable sell-off. Market participants will now look to the May 11 announcement for crucial details regarding the company's financial standing and future strategy.

FAQ

Q: Why did Daiichi Sankyo's stock price fall?
A: The stock fell 10.4% after the company delayed its Q4 earnings report for a second time to calculate a new loss provision for a development-stage product.

Q: What is the new date for Daiichi Sankyo's earnings release?
A: The fourth-quarter results and the new medium-term plan are now scheduled for release on May 11.

Source: Investing.com